Sarah Donahue, MPH, NP
University of California San Francisco Helen Diller Family Comprehensive Cancer CenterAuthored Items
October 25, 2019 | November 2019 Vol 10, No 11
Activating mutations in PIK3CA (the gene encoding the p110α catalytic subunit of class I phosphatidylinositol 3-kinase [PI3K] [PI3Kα]) lead to increased activity of the PI3K pathway and play a role in endocrine treatment resistance in breast cancer.
Last modified: November 6, 2019